Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil.
Anna Maria BuehlerPierre-Alexandre DionneDavid ChandiwanaPurnima PathakEbuwa Igho-OsagiePublished in: Revista de saude publica (2022)
The phase III MONALEESA-7 trial productivity results applied to the Brazilian premenopausal prevalent cases of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer showed that treatment with ribociclib + endocrine therapy improves workforce participation compared with endocrine therapy alone in premenopausal women with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer, with potential economic gains for the Brazilian society.
Keyphrases
- epidermal growth factor receptor
- phase iii
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- metastatic breast cancer
- clinical trial
- open label
- climate change
- postmenopausal women
- phase ii
- breast cancer risk
- pluripotent stem cells
- public health
- physical activity
- stem cells
- double blind
- placebo controlled
- risk assessment
- mesenchymal stem cells
- combination therapy
- early breast cancer
- life cycle